FOXP3 and type 1 diabetes mellitus: Thus, understanding the mechanisms that regulate alternative FOXP3 splicing and exploiting the chemical factors that control this process may enable Treg activity to be modulated in vitro and in situ, providing an alternative therapy for a number of autoimmune diseases, including T1D.